

How we have learned about the complexity of physiology, pathobiology and pharmacology of bile acids and biliary secretion

Jose JG Marin

Jose JG Marin, Laboratory of Experimental Hepatology and Drug Targeting, CIBERehd, University of Salamanca, Salamanca 37007, Spain

Author contributions: Marin JJG is the sole contributor to this paper.

Correspondence to: Jose JG Marin, Professor, Department of Physiology and Pharmacology, Campus Miguel de Unamuno E.I.D. S-09, Salamanca 37007, Spain. jjgmarin@usal.es

Telephone: +34-923-294674 Fax: +34-923-294669

Received: July 24, 2008 Revised: September 16, 2008

Accepted: September 23, 2008

Published online: October 7, 2008

Abstract

During the last decades the concept of bile secretion as merely a way to add detergent components to the intestinal mixture to facilitate fat digestion/absorption and to eliminate side products of heme metabolism has evolved considerably. In the series of mini-reviews that the *World Journal of Gastroenterology* is to publish in its section of "Highlight Topics", we will intend to give a brief but updated overview of our knowledge in this field. This introductory letter is intended to thank all scientists who have contributed to the development of this area of knowledge in gastroenterology.

© 2008 The WJG Press. All rights reserved.

Key words: Bile flow; Cholestasis; Hepatocyte; Liver; Transport

Marin JJG. How we have learned about the complexity of physiology, pathobiology and pharmacology of bile acids and biliary secretion. *World J Gastroenterol* 2008; 14(37): 5617-5619 Available from: URL: <http://www.wjgnet.com/1007-9327/14/5617.asp> DOI: <http://dx.doi.org/10.3748/wjg.14.5617>

INTRODUCTION

During the last decades the concept of bile secretion as merely a way to add detergent components to the intestinal mixture to facilitate fat digestion/absorption and to eliminate side products of heme metabolism has evolved

considerably. In the series of mini-reviews that the *World Journal of Gastroenterology* is to publish in its section of "Highlight Topics", we intend to give a brief but updated overview of our knowledge in this field. The first opening title by Esteller^[1], in addition to review the mechanisms of bile formation, will serve as an introduction to the rest of mini-reviews. Therefore, I will skip this task here and devote this letter to thank all scientists who have contributed to the development of this area of knowledge in gastroenterology. First of all, I wish to apologize because only a limited number of them will be cited here and also for the fact that, in most cases, I will cite them by the main investigator of the group. I assume that we all know, in some cases personally, what excellent scientists have participated in the contributions published by these teams. Nevertheless, I hope that every important contribution and research group will be cited in the appropriate mini-review of the series. Let me start this brief historical overview by reminding you the important initial steps in understanding bile acid physiology given by Schiff^[2] and Wheeler^[3], which permitted the establishment of the bases for further investigations by Boyer^[4], Erlinger^[5], Anwer^[6] and others on the role of osmotic mechanisms accounting for bile acid-dependent and-independent fractions of bile flow. The elucidation of the physical-chemical characteristics of bile acids has been determinant in understanding the role of different bile acid species in bile formation, bile acid-induced injury of liver tissue and cholestasis or, in contrast, hepatoprotection, as well as the process of gallstone formation or prevention, etc. This has been possible thanks to the investigations carried out by many groups, including those of Hofmann^[7], Carey^[8], Small^[7,8], Paumgartner^[9], Reichen^[9], Danielsson^[10], Sjoval^[10], Reyes^[11], Setchell^[12], Poupon^[13] and others. It has been with the help of molecular biology techniques that Meier^[14,15], Stieger^[14], Hagenbuch^[15,16], Keppler^[17], Thompson^[18] and others have been able to identify transport proteins involved in the efficient uptake and secretion of bile acids by the liver. Similar studies by Dawson^[16] and others have also contributed to our understanding of the role of intestinal transporters in the so-called enterohepatic circulation of bile acids. Advances in the research of substrate-transporter interactions by many important groups, including several mentioned above in addition to those of Sugiyama^[19], Klaassen^[20] and Petzinger^[21], has led to Kramer^[22] and others, including

our own laboratory^[23,24] to undertake the development of promising new drugs based on the substrate selectivity of plasma membrane transporters and the possibility of either blocking their function or targeting bile acid derivatives toward healthy liver tissue or toward tumours located in the enterohepatic circuit. Over the last few years the novel concept of bile acids as signalling molecules in several cell types has emerged. Thus, the possibility that bile acids, as well as other oxysterols, may activate nuclear receptors and regulate the expression of enzymes and transporters was suggested from results obtained at the same time by three different groups^[25-27], and developed by these groups, and others, such as those of Karpen^[28], Kullak-Ublick^[29], Chiang^[30] and Houten^[31]. These findings are helping us to understand how liver cells may respond to endocrine signals (e.g. during pregnancy) or to the accumulation of bile acids occurring in cholestasis, which is the subject of research currently carried out by several groups, including those of Trauner^[32,33], Suchy^[33,34], Ananthanarayanan^[33,34], Lammert^[35], Williamson^[35], Accatino^[33], Arrese^[33,36] and others. Moreover, bile acids can also interact with plasma membrane elements and therefore participate in autocrine and paracrine functions, interacting with several signalling pathways as it is being brilliantly investigated by Haussinger, Kubitz, Keitel and the rest of this group^[37], as well as by Dent^[38], Fujino^[39], Beuers^[40], Dufour^[41] and others. A complete view of biliary physiology also needs to consider the participation of cholangiocytes in bile formation and the knowledge of mechanisms of bile secretion of other important endogenous compounds, such as cholesterol, bilirubin, glutathione and xenobiotics, such as drugs and toxins. We owe many important contributions in these fields to LaRusso^[42], Ballatori^[43], Arias^[44], Keppler^[17], Sugiyama^[19], Wolkoff^[45], Oude Elferink^[46], Meijer^[46], Kuipers^[46], Jansen^[46], Groen^[46], Groothuis^[46], Ostrow^[47], Fevery^[48], Coleman^[49], Berenson^[50], Vore^[51] and many others. As I said this editorial letter of gratitude is highly incomplete, but it would be even more so without mentioning the appreciation of many hepatologists to the supporting role of Dr. Falk and the Falk Foundation e.V. to the research in this field.

REFERENCES

- 1 **Esteller A**, Lopez MA. The effect of secretin and cholecystokinin-pancreozymin on the secretion of bile in the anaesthetized rabbit. *Q J Exp Physiol Cogn Med Sci* 1977; **62**: 353-359
- 2 **Schiff MI**. Gallenbildung, abhängig von der Aufsaugung der Gallenstoffe. *Arch Ges Physiol Menschen Tiere* 1870; **3**: 598-613
- 3 **Wheeler HO**. Secretion of bile acids by the liver and their role in the formation of hepatic bile. *Arch Intern Med* 1972; **130**: 533-541
- 4 **Boyer JL**. New concepts of mechanisms of hepatocyte bile formation. *Physiol Rev* 1980; **60**: 303-326
- 5 **Erlinger S**. Physiology of bile flow. *Prog Liver Dis* 1972; **4**: 63-82
- 6 **Anwer MS**, Hegner D. Importance of solvent drag and diffusion in bile acid-dependent bile formation: ion substitution studies in isolated perfused rat liver. *Hepatology* 1982; **2**: 580-586
- 7 **Hofmann AF**, Small DM. Detergent properties of bile salts: correlation with physiological function. *Annu Rev Med* 1967; **18**: 333-376
- 8 **Carey MC**, Small DM. The characteristics of mixed micellar solutions with particular reference to bile. *Am J Med* 1970; **49**: 590-608
- 9 **Paumgartner G**, Reichen J, von Bergmann K, Preisig R. Elaboration of hepatocytic bile. *Bull N Y Acad Med* 1975; **51**: 455-471
- 10 **Danielsson H**, Sjoval J. Bile acid metabolism. *Annu Rev Biochem* 1975; **44**: 233-253
- 11 **Reyes H**. Review: intrahepatic cholestasis. A puzzling disorder of pregnancy. *J Gastroenterol Hepatol* 1997; **12**: 211-216
- 12 **Setchell KD**, Street JM. Inborn errors of bile acid synthesis. *Semin Liver Dis* 1987; **7**: 85-99
- 13 **Poupon RE**, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. *N Engl J Med* 1991; **324**: 1548-1554
- 14 **Meier PJ**, Stieger B. Bile salt transporters. *Annu Rev Physiol* 2002; **64**: 635-661
- 15 **Hagenbuch B**, Meier PJ. The superfamily of organic anion transporting polypeptides. *Biochim Biophys Acta* 2003; **1609**: 1-18
- 16 **Hagenbuch B**, Dawson P. The sodium bile salt cotransport family SLC10. *Pflugers Arch* 2004; **447**: 566-570
- 17 **Keppler D**, König J. Hepatic secretion of conjugated drugs and endogenous substances. *Semin Liver Dis* 2000; **20**: 265-272
- 18 **Strautnieks SS**, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, Sokal E, Dahan K, Childs S, Ling V, Tanner MS, Kagalwalla AF, Nemeth A, Pawlowska J, Baker A, Mielivergani G, Freimer NB, Gardiner RM, Thompson RJ. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. *Nat Genet* 1998; **20**: 233-238
- 19 **Shitara Y**, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. *Annu Rev Pharmacol Toxicol* 2005; **45**: 689-723
- 20 **Klaassen CD**. Biliary excretion of xenobiotics. *CRC Crit Rev Toxicol* 1975; **4**: 1-30
- 21 **Petzinger E**, Geyer J. Drug transporters in pharmacokinetics. *Naunyn Schmiedeberg's Arch Pharmacol* 2006; **372**: 465-475
- 22 **Kramer W**, Wess G. Bile acid transport systems as pharmaceutical targets. *Eur J Clin Invest* 1996; **26**: 715-732
- 23 **Dominguez MF**, Macias RI, Izco-Basurko I, de La Fuente A, Pascual MJ, Criado JM, Monte MJ, Yajeya J, Marin JJ. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. *J Pharmacol Exp Ther* 2001; **297**: 1106-1112
- 24 **Briz O**, Macias RI, Vallejo M, Silva A, Serrano MA, Marin JJ. Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors. *Mol Pharmacol* 2003; **63**: 742-750
- 25 **Makishima M**, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. *Science* 1999; **284**: 1362-1365
- 26 **Parks DJ**, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM. Bile acids: natural ligands for an orphan nuclear receptor. *Science* 1999; **284**: 1365-1368
- 27 **Wang H**, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. *Mol Cell* 1999; **3**: 543-553
- 28 **Karpen SJ**. Nuclear receptor regulation of hepatic function. *J Hepatol* 2002; **36**: 832-850
- 29 **Eloranta JJ**, Kullak-Ublick GA. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. *Arch Biochem Biophys* 2005; **433**: 397-412
- 30 **Chiang JY**. Bile acid regulation of gene expression: roles of nuclear hormone receptors. *Endocr Rev* 2002; **23**: 443-463

- 31 **Houten SM**, Watanabe M, Auwerx J. Endocrine functions of bile acids. *EMBO J* 2006; **25**: 1419-1425
- 32 **Zollner G**, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. *Mol Pharm* 2006; **3**: 231-251
- 33 **Arrese M**, Trauner M, Ananthanarayanan M, Pizarro M, Solis N, Accatino L, Soroka C, Boyer JL, Karpen SJ, Miquel JF, Suchy FJ. Down-regulation of the Na⁺/taurocholate cotransporting polypeptide during pregnancy in the rat. *J Hepatol* 2003; **38**: 148-55
- 34 **Suchy FJ**, Ananthanarayanan M. Bile salt excretory pump: biology and pathobiology. *J Pediatr Gastroenterol Nutr* 2006; **43** Suppl 1: S10-S16
- 35 **Van Mil SW**, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, Shevchuk V, Moore GE, Lammert F, Glantz AG, Mattsson LA, Whittaker J, Parker MG, White R, Williamson C. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. *Gastroenterology* 2007; **133**: 507-516
- 36 **Arrese M**, Macias RI, Briz O, Perez MJ, Marin JJ. Molecular pathogenesis of intrahepatic cholestasis of pregnancy. *Expert Rev Mol Med* 2008; **10**: e9
- 37 **Keitel V**, Reinehr R, Gatsios P, Rupprecht C, Gorg B, Selbach O, Haussinger D, Kubitz R. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. *Hepatology* 2007; **45**: 695-704
- 38 **Dent P**, Fang Y, Gupta S, Studer E, Mitchell C, Spiegel S, Hylemon PB. Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes. *Hepatology* 2005; **42**: 1291-1299
- 39 **Kawamata Y**, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, Fujino M. A G protein-coupled receptor responsive to bile acids. *J Biol Chem* 2003; **278**: 9435-9440
- 40 **Wimmer R**, Hohenester S, Pusch T, Denk GU, Rust C, Beuers U. Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC{alpha}-/PKA-dependent mechanism in rat liver. *Gut* 2008; **57**: 1448-1454
- 41 **Wang L**, Piguat AC, Schmidt K, Tordjmann T, Dufour JF. Activation of CREB by tauroursodeoxycholic acid protects cholangiocytes from apoptosis induced by mTOR inhibition. *Hepatology* 2005; **41**: 1241-1251
- 42 **Bogert PT**, LaRusso NF. Cholangiocyte biology. *Curr Opin Gastroenterol* 2007; **23**: 299-305
- 43 **Ballatori N**, Hammond CL, Cunningham JB, Krance SM, Marchan R. Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. *Toxicol Appl Pharmacol* 2005; **204**: 238-255
- 44 **Arias IM**. Hepatic aspects of bilirubin metabolism. *Annu Rev Med* 1966; **17**: 257-274
- 45 **Wolkoff AW**. Hepatocellular sinusoidal membrane organic anion transport and transporters. *Semin Liver Dis* 1996; **16**: 121-127
- 46 **Oude Elferink RP**, Meijer DK, Kuipers F, Jansen PL, Groen AK, Groothuis GM. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. *Biochim Biophys Acta* 1995; **1241**: 215-268
- 47 **Ostrow JD**. Photochemical and biochemical basis of the treatment of neonatal jaundice. *Prog Liver Dis* 1972; **4**: 447-462
- 48 **Feverly J**, Blanckaert N, Heirwegh KP, De Groote J. Bilirubin conjugates: formation and detection. *Prog Liver Dis* 1976; **5**: 183-214
- 49 **Coleman R**. Bile salts and biliary lipids. *Biochem Soc Trans* 1987; **15** Suppl: 68S-80S
- 50 **Berenson MM**, Marin JJ, Larsen R, Avner D. Effect of bile acids on hepatic protoporphyrin metabolism in perfused rat liver. *Gastroenterology* 1987; **93**: 1086-1093
- 51 **Vore M**. Canalicular transport: discovery of ATP-dependent mechanisms. *Toxicol Appl Pharmacol* 1993; **118**: 2-7

S- Editor Li DL E- Editor Lin YP